NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb
Company (NYSE: BMY) announced today that it has agreed to sell $1.6 billion
of senior unsecured notes: $600 million in aggregate principal amount of
5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount
of 6.125% notes due May 1, 2038 in an underwritten public offering.
Banc of America Securities LLC, J.P. Morgan Securities Inc., and Morgan
Stanley are acting as representatives of the underwriters.
Bristol-Myers Squibb intends to use the net proceeds from the offering
to finance the repayment of its $400 million principal amount of the 4.00%
Notes due August 2008, to finance redemptions of its $1.2 billion principal
amount of Floating Rate Convertible Debentures due 2023 at the option of
holders in 2008 and general corporate purposes. The offering is expected to
close on May 1, 2008.
The prospectus supplement and accompanying prospectus related to the
offering of the notes may be obtained by contacting one of the following
representatives:
Banc of America Securities, LLC
Capital Markets Operations
100 West 33rd Street, 3rd Floor
New York, NY 10001
Telephone: 800-294-1322
J.P. Morgan Securities Inc.
270 Park Avenue, 8th Floor
New York, NY 10017
Telephone: 212-834-4533
Morgan Stanley and Company, Inc.
180 Varick Street 2/F
New York, NY 10014
Attention: Prospectus Department
Telephone: 866-718-1649
Forward-Looking Statements
This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual outcomes and results
to differ materially from current expectations. No forward-looking
statement can be guaranteed. Forward-looking statements in this press
release should be evaluated together with the many risks and uncertainties
that affect Bristol-Myers Squibb's business, including those identified in
Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2007, particularly under "Item 1A. Risk Factors".
Bristol-Myers Squibb undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical and related health
care products company whose mission is to extend and enhance human life.
SOURCE Bristol-Myers Squibb Company
 back to top
Related links:
http://www.bms.com/
CONTACT:
Media: Brian Henry, Communications,
+1-609-252-3337, brian.henry@bms.com; Investors: John Elicker,
Investor Relations, +1-212-546-3775, john.elicker@bms.com
|
